Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk

Novo Nordisk A/S
Posted on: 16 Sep 16

Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk. 1 These results were based on an accumulation of first major adverse CV events (MACE) in 254 people. 1

The main results from SUSTAIN 6 were presented today at the 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016 2 and also published in the New England Journal of Medicine . 1

 

Further information

Media:    
Katrine Sperling+45 4442 6718 krsp@novonordisk.com
Åsa Josefsson+45 3079 7708 aajf@novonordisk.com
     
Investors :    
Peter Hugreffe Ankersen+45 3075 9085 phak@novonordisk.com
Melanie Raouzeos+45 3075 3479 mrz@novonordisk.com
Hanna Ögren+45 3079 8519 haoe@novonordisk.com
Kasper Veje (US)+1 609 235 8567 kpvj@novonordisk.com

References

 

  1. Marso SP, Bain S, ConsoliA, et al . Semaglutide and cardiovascular outcomes, efficacy and safety in type 2 diabetes. New England Journal of Medicine. 2016; In Press.
Read the full release including references


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire
HUG#2042547
GlobeNewswire
globenewswire.com

Last updated on: 17/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.